First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study

OBJECTIVE: To investigate the pharmacodynamics, pharmacokinetics and safety of cenerimod—a potent, oral, selective sphingosine 1-phosphate 1 receptor modulator—in patients with SLE. METHODS: This multicentre, double-blind, placebo-controlled study was conducted in two parts. In part A, patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermann, Viktoria, Batalov, Anastas, Smakotina, Svetlana, Juif, Pierre-Eric, Cornelisse, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861098/
https://www.ncbi.nlm.nih.gov/pubmed/31798918
http://dx.doi.org/10.1136/lupus-2019-000354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861098/
https://www.ncbi.nlm.nih.gov/pubmed/31798918
http://dx.doi.org/10.1136/lupus-2019-000354

Ejemplares similares